

ADDITIONAL FILE 1

Section A: Variable Definitions

Section B: Patient characteristics by exposure

Section C: SMDI commands

Section D: ASMD tables for each partially observed covariate

Section A: Variable Definitions

Definitions: Inclusion and exclusion criteria

Inclusion criteria	Codes/Medications	Setting/Position
Medication: DPP4 inhibitor	Generic name: Canagliflozin, Dapagliflozin, Empagliflozin, or Ertugliflozin	New dispensing between Oct 2015 – Dec 2017 without evidence of either med in prior 12 months and no SGLt2i dispensed the same day
Medication: SGLt2 inhibitor	Generic name: Alogliptin, Saxagliptin, Linagliptin, or Sitagliptin	New dispensing between Oct 2015 – Dec 2017 without evidence of either med in prior 12 months and no DPP4i dispensed the same day
Medicare Part A and B enrollment		Continuous enrollment in Parts A and B from index date till end-of-followup and 12 months prior to index date
Medicare Part D enrollment		Continuous enrollment in Part D from index date till end-of-followup and 12 months prior to index date
Prior enrollment (EHR)		Any in-person EHR encounter 12 months prior to index date
Type 2 diabetes mellitus	ICD 9 diagnosis: 250.00, 250.02, 250.10, 250.12, 250.20, 250.22, 250.30, 250.32, 250.40, 250.42, 250.50, 250.52, 250.60, 250.62, 250.70, 250.72, 250.80, 250.82, 250.90, 250.92 ICD 10 diagnosis: E11.x	Inpatient or outpatient setting, at least 1 in any position 12 months prior to index date
Exclusion criteria	Codes	
Type 1 diabetes mellitus	ICD 9 diagnosis: 250.01, 250.03, 250.11, 250.13, 250.21, 250.23, 250.31, 250.33, 250.41, 250.43, 250.51, 250.53, 250.61, 250.63, 250.71, 250.73, 250.81, 250.83, 250.91, 250.93 ICD 10 diagnosis: E10.x	Inpatient or outpatient setting, at least 1 in any position 12 months prior to index date

Secondary and gestational diabetes	ICD 9 diagnosis: 249.x, 648.8x ICD 10 diagnosis: E08.x, E09.x, O24.4x, O99.81	Inpatient or outpatient setting, at least 1 in any position 12 months prior to index date
End-stage renal disease (dialysis or renal transplant)	ICD-9 diagnosis: 585.5, 585.6, 996.81, V42.0, V45.1x, V56.xx ICD-9 procedure: 39.95, 54.98, 55.6x ICD-10 diagnosis: N18.5, N18.6, R88.0, T82.41x, T82.42x, T82.43x, T82.49x, T85.611x, T85.621x, T85.631x, T85.71x, T86.1x, Y84.1, Z48.22, Z49.xx, Z91.15, Z94.0, Z99.2 ICD-10 procedure: 0TY00Zx, 0TY10Zx, 3E1M39Z, 5A1Dx0Z HCPCS/CPT: 50360, 50365, 90920, 90921, 90924, 90925, 90935, 90937, 90939, 90940, 90945, 90947, 90957, 90958, 90959, 90960, 90961, 90962, 90965, 90966, 90969, 90970, 90989, 90993, 90999, 90997, 99512, 99559, 99512, G0257, G0314, G0315, G0316, G0317, G0318, G0319, G0322, G0323, G0326, G0327, S9335, S9339	Inpatient or outpatient setting, at least 1 in any position 12 months prior to index date
Human immunodeficiency virus (HIV)	ICD 9 diagnosis: 042, 043, 044 ICD 10 diagnosis: B20	Inpatient or outpatient setting, at least 1 in any position 12 months prior to index date
Malignancy (excluding non-melanoma skin cancer)	ICD 9 diagnosis: 140.x-209.x (except 173.x, non-melanoma skin cancer and 209.4x, 209.5x, 209.6x) ICD 10 diagnosis: C00.x-C96, D03.x, D45 (except C44.x, non-melanoma skin cancer)	Inpatient or outpatient setting, at least 1 in any position 12 months prior to index date
Skilled nursing facility admission	Claims in SNF dataset CPT codes: 99301, 99302, 99303, 99311, 99312, 99313, 99315, 99316, 99379, 99380, G0066 Place of service code: 31 (skilled nursing facility), 32 (nursing facility), 33 (custodial care facility)	Inpatient or outpatient setting, at least 1 in any position 12 months prior to index date
Organ and tissue transplant	ICD 9 diagnosis: V42.x ICD 10 diagnosis: Z94.x	Inpatient or outpatient setting, at least 1 in any position 12 months prior to index date
Demographic variables: Age and gender		Missing age or gender

Definitions: Outcome and Exposure

Outcome	Component	Diagnosis and/or Procedure Codes	Setting/Position
Primary Outcome (variable name)			
Modified MACE (outcome_MACE and time_to_event)	Myocardial Infarction	ICD-9 diagnosis: 410.x ICD-10 diagnosis: I21.x (excluding I21.9, I21.Ax)	Inpatient or outpatient, primary or secondary position

	Stroke	ICD-9 diagnosis: 430, 431, 433.x1, 434.x1, 436 ICD-10 diagnosis: I60.x, I61.x, I63.x, I67.89	Inpatient or outpatient, primary or secondary position
	All-cause mortality	Information on mortality was available through four sources: Centers for Medicare and Medicaid Services, Social Security Administration Master Death Files, in-hospital deaths, and death as a reason for insurance discontinuation.	
Exposure			
Medication (Exposure_medication) (binary)	SGLt2 vs DDD4 inhibitor	See inclusion criteria	

Definitions: Other Comorbidities (during 12 months prior to index date)

Comorbidity	Codes	Setting/Position
Atrial fibrillation[1-3] (atrial_fib)	ICD 9 diagnosis: 427.31 ICD 10 diagnosis: I48.x	Inpatient or outpatient setting, any position
Anemia (anemia)	ICD-9 diagnosis: 250.1x ICD-10 diagnosis: E10.1x, E11.1x, E13.1x	Inpatient or outpatient setting, any position
Cardiomyopathy (cardiomyopathy)	ICD 9 diagnosis: 425.x, 674.5, ICD 10 diagnosis: A36.81, B33.24, I25.5, I42.x, I43.x, O90.3	Inpatient or outpatient setting, any position
Hyperglycemia[4] (hyperglycemia)	ICD-9 diagnosis: 250.02, 250.03, 250.1, 250.2, 250.3 ICD-10 diagnosis: E08.65, E09.65, E10.65, E11.65, E13.65, R73.9	Inpatient or outpatient setting, any position
Stroke/Ischemia/TIA[5] (stroke_tia)	ICD-9 diagnosis: 430.x, 431.x, 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.x, 436.x, 437.0, 437.1 ICD 10 diagnosis: I60.x, I61.x, I63.x, I67.2, I67.81, I67.82, I67.89	Inpatient or outpatient setting, any position
Diabetic neuropathy (diabetic_neuropathy)	ICD-9 diagnosis: 250.6, 249.6 ICD-10 diagnosis: E08.4, E09.4, E10.4, E11.4, E13.4	Inpatient or outpatient setting, any position
Diabetes with peripheral circulatory disorders (diabetes_circulatory_disorders)	ICD-9 diagnosis: 250.7, 249.7 ICD-10 diagnosis: E08.5, E09.5, E10.5, E11.5, E13.5	Inpatient or outpatient setting, any position
Pulmonary hypertension (pulmonary_hypertension)	ICD-9 diagnosis: 416.0, 416.8, 416.9 ICD-10 diagnosis: I27.0, I27.2	Inpatient or outpatient setting, any position
Acute kidney injury (acute_kidney_injury)	ICD-9 diagnosis: 584.x ICD-10 diagnosis: N17.x	Inpatient or outpatient setting, any position

Chronic kidney disease (chronic_kidney_disease)	ICD-9 diagnosis: 585.x ICD-10 diagnosis: N18.x	Inpatient or outpatient setting, any position
Dementia (dementia)	ICD-9 diagnosis: 290.x, 294.1, 331.2 ICD-10 diagnosis: F01.x, F02.x, F03.9x, G31.1	Inpatient or outpatient setting, any position
Alzheimer's disease (alzheimers_disease)	ICD-9 diagnosis: 331.0 ICD-10 diagnosis: G30.x	Inpatient or outpatient setting, any position
Chronic obstructive pulmonary disease (COPD)	ICD-9 diagnosis: 491.x, 492.x, 496.x ICD-10 diagnosis: J4.x 1, J42.x, J43.x, J44.x	Inpatient or outpatient setting, any position
Depression (depression)	ICD-9 diagnosis: 296.2, 296.3, 296.5, 300.4, 309.x, 311.x ICD-10 diagnosis: F31.3, F31.4, F31.5, F31.75, F31.76, F32.x, F33.x, F34.1, F43.10, F43.11, F43.12, F43.2, F43.8, F43.9, F93.0, F94.8	Inpatient or outpatient setting, any position
Unstable Angina (unstable_angina)	ICD-9 diagnosis: 411.1 ICD-10 diagnosis: I20.0	Inpatient or outpatient setting, any position
Obesity (obesity_diagnosis)	Obese ICD-9 diagnosis: V85.3, V85.30, V85.31, V85.32, V85.33, V85.34, V85.35, V85.36, V85.37, V85.38, V85.39 Obese ICD-10 diagnosis: E66.0, Z68.30, Z68.31, Z68.32, Z68.33, Z68.34, Z68.35, Z68.36, Z68.37, Z68.38, Z68.39 Severely Obese ICD-9 diagnosis: 278.01, V85.4, V85.40, V85.41, V85.42, V85.43, V85.44, V85.45 Severely Obese ICD-10 diagnosis: E66.01, E66.2, Z68.4, Z68.41, Z68.42, Z68.43, Z68.44, Z68.45	Inpatient or outpatient setting, any position
Charlson Comorbidity Index (Charlson_Index)		
Faurot Frailty Index[6] (Faurot_Frailty_Index)		

Definitions: EHR covariates

Covariate (variable name)		
HbA1c (continuous) (EHR_Hba1c)		Closest HbA1c value to index in the 12 months preceding medication index
BMI (categorical) (EHR_BMI)	BMI <18.5 = underweight 18.5-24.9 = healthy weight 25.0-29.9 = overweight ≥30 = obese	Closest BMI to index in the 12 months preceding medication index

Definitions: Medications for other treatment

Medication	Generic name	Setting/Position
Sulfonylureas (sulfonylureas_4mths)	Gliclazide, glipizide, glibenclamide, glimepiride, tolbutamide, chlorpropamide	At least 1 fill recorded within 4 months before and including index date

Metformin (metformin_4mths)	Metformin	At least 1 fill recorded within 4 months before and including index date
Insulin (insulin_4mths)	Insulin	At least 1 fill recorded within 4 months before and including index date
Anticoagulant (anticoagulant_12mths)	Warfarin, apixaban, dabigatran, edoxaban, rivaroxaban	At least 1 fill recorded within 12 months before and including index date
Antiplatelet (antiplatelet_12mths)	Acetylsalicylic, asa, aspirin, clopidogrel, prasugrel, ticagrelor, ticlopidine, dipyridamole, cilostazol, anagrelide, cangrelor, vorapaxar	At least 1 fill recorded within 12 months before and including index date
Statins (statins_12mths)	Atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin	At least 1 fill recorded within 12 months before and including index date
Antihypertensives[7] (antihypertensives_12mths)	Angiotensin II type 2 and 4 stimulating: amlodipine, bendroflumethiazide, candesartan, chlorthalidone, prosartan, hydrochlorothiazide, hydroflumethiazide, irbesartan, isradipine, methyclothiazide, nifedipine, nimodipine, nisoldipine, polythiazide, telmisartan, valsartan Angiotensin II type 2 and 4 inhibiting: acebutolol, benazepril, bepridil, bisoprolol, captopril, carvedilol, diltiazem, fosinopril, labetalol, metoprolol, mibefradil, nadolol, nisoldipine, polythiazide, nebivolol, perindopril, pindolol, quinapril, ramipril, timolol, trandolapril, verapamil Other: acetazolamide, ambrisentan, amiloride, bumetanide, clonidine, dipyridamole, doxazosin, ergoloid, mesylates, ethaverine, furosemide, guanadrel, guanethidine, hydralazine, isoxsuprine, mannitol, mecamlamine, metolazone, minoxidil, papaverine, phenoxybenzamine, rauwolfia, serpentina, riociguat, sacubitril, spironolactone, terazosin, torsemide, treprostinil, triamterene	At least 1 fill recorded within 12 months before and including index date

Definitions: Health Care Utilization Measures during 12 months prior to index date

Measure	Component Codes and/or specialty	Setting/Position
Hospitalizations (continuous) (hospitalizations_12mths)	Provider codes for Traditional acute care hospitals: 0001-0879 Provider codes for Critical access hospitals: 1300-1399	Inpatient or outpatient setting
ED visits (continuous) (ed_visits_12mths)	ED revenue codes: 0450-0459, 0981, 0762 Excluded procedure codes for only radiological or pathology/laboratory services: 70000-79999, 80000-89999	Inpatient or outpatient setting

Internal medicine visits (continuous) (internal_med_12mths)	Specialty: 01, 08, 11	Inpatient or outpatient setting
Endocrinology visits (continuous) (endocrinology_visits_12mths)	Specialty: 46	Inpatient or outpatient setting
Flu shot (binary) (flu_shot_12mths)	CPT: 90630, 90653, 90654, 90655, 90656, 90657, 90658, 90660, 90662, 90672, 90673, 90674, 90682, 90685, 90686, 90687, 90688, 90689, 90694, 90756, Q2034, Q2035, Q2036, Q2037, Q2038, Q2039, G0008	Inpatient or outpatient setting
Colonoscopy (binary) (colonscopy_12mths)	CPT: 45378-45398 HCPCS: G0105, G0121	Inpatient or outpatient setting
Medicare part D cost share (categorical) (MedicarePartD_costshare)	No cost sharing, 100% premium subsidy, 75% premium subsidy, 50% premium subsidy, 25% premium subsidy	Part D Denominator file

Section B

Table. Selected baseline characteristics of participants initiating SGLT2 inhibitor vs DPP-4i medication.			
Baseline characteristic	SGLT2i (n = 387)	DPP4i (n = 1715)	SMD
Age, years			
Mean (SD)	64.6 (10.5)	69.8 (11.1)	0.48
Sex, female, n (%)	204(52.7)	977(57.0)	0.08
Race, n (%)			0.17
White	267 (69.0)	1071 (62.5)	
Black	99 (25.6)	488 (28.5)	
Other	21 (5.4)	156 (9.1)	
Charlson Comorbidity Score			0.23
0	15 (3.9)	83 (4.8)	
1	126 (32.6)	484 (28.2)	
2	65 (16.6)	230 (13.4)	
3	70 (18.1)	280 (16.2)	
4	45 (11.62)	200 (25.5)	
5+	66 (17.1)	438 (25.5)	
Medical history (prior 12 months)			
Atrial fibrillation	31 (8.0)	260 (15.2)	0.23
Anemia	78 (20.2)	514 (30.0)	0.23
Cardiomyopathy	29 (7.5)	157 (9.2)	0.06
Hyperglycemia	239 (61.8)	766 (44.7)	0.35
Stroke/ischemia/TIA	25 (6.5)	120 (7.0)	0.02
Unstable angina	2 (0.5)	4 (0.2)	0.05
Diabetic neuropathy	111 (28.7)	414 (24.1)	0.10
Diabetes with peripheral circulatory disorders	33 (8.5)	138 (8.0)	0.02
Pulmonary hypertension	2 (0.52)	12 (0.70)	0.02
Acute kidney injury	17 (4.39)	141 (8.22)	0.16
Chronic kidney disease	36 (9.3)	352 (20.52)	0.32
COPD	48 (12.4)	207 (12.07)	0.01
Alzheimer's	1 (0.26)	25 (1.46)	0.13
Dementia	4 (1.03)	64 (3.73)	0.18
Depression	51(13.2)	228 (13.3)	<0.01

Faurot Frailty Index (mean, SD)	0.05 (0.07)	0.06 (0.07)	0.12
Medication use (prior 4 months)			
sulfonylureas	153 (39.5)	684 (39.9)	<0.01
metformin	282 (72.9)	1067 (62.2)	0.23
insulin	132 (34.1)	428 (25.0)	0.20
Medication use (prior 12 months)			
Anticoagulants	38 (9.8)	229 (13.4)	0.11
Antiplatelets	58 (15.0)	251 (14.6)	0.01
Statins	307 (79.3)	1341 (78.2)	0.03
Antihypertensives	361 (93.3)	1615 (94.2)	0.04
*HbA1c value (mean, SD)	8.0 (1.5)	7.8 (1.6)	0.12
Missing	279 (72.1)	1058 (61.7)	
*BMI			0.24
Underweight	0 (0.0)	8 (0.5)	
Normal Weight	18 (4.7)	139 (8.1)	
Overweight	81 (20.9)	422 (24.6)	
Obese	226 (58.4)	862 (50.3)	
Missing	62(16.0)	284 (16.6)	
Health care use (prior 12 months)			
Hospitalizations (mean, SD)	0.3 (0.8)	0.3 (0.7)	0.07
ED encounters (mean, SD)	1.0 (2.5)	0.9 (2.3)	0.05
Flu shot	15 (3.9)	115 (6.7)	0.13
Colonoscopy	19 (4.9)	81 (4.7)	<0.01
Endocrinology visits (mean, SD)	0.1 (0.5)	0.07 (0.5)	0.05
Internal medicine visits (mean, SD)	2.4 (3.5)	2.8 (3.4)	0.12
Medicare part D cost share (categorical)	165 (42.6)	726 (42.3)	<0.01

Section C: SMDI commands

For each figure or table, the corresponding code is indicated. Yellow text indicate format-related code.

Figure 2: SMDI descriptive output.

```
data %>% smdi_vis() + theme(text = element_text(size=20), axis.text= element_text(size=18))
```

```
data %>% smdi_vis(strata = "Exposure_medication") + theme(text = element_text(size=20), axis.text= element_text(size=18))
```

Figure 3: SMDI descriptive functions

```
data %>% gg_miss_upset(point.size = 3.2, text.scale = 2)
```

Table 2: SMDI_diagnose results for multiple partially observed covariates.

```
smdi_diagnose(data,  
              covar = NULL,  
              model = "cox",  
              form_lhs = "Surv(time_to_event_MACE, Outcome_MACE)"  
              )
```

Figure 4: Group 1 diagnostics. ASMD plot for a) HbA1c, and b) BMI.

```
asmd_output <- smdi_asmd(data, median = TRUE, includeNA = FALSE)  
asmd_output$EHR_BMI$asmd_table1  
asmd_output$EHR_BMI$asmd_plot + theme(text = element_text(size=16), axis.text= element_text(size=14))
```

Figure 5: Group 2 diagnostics. a) Covariate importance for predicting HbA1c missingness, c) Covariate importance for predicting BMI missingness.

```
auc_output <- smdi_rf(data, train_test_ratio = c(.7, .3), set_seed = 123)  
auc_output$EHR_BMI$rf_table  
auc_output$EHR_BMI$rf_plot + theme(text = element_text(size=16), axis.text= element_text(size=14))
```

Section D ASMD tables for each partially observed covariate

Table: Standardized Mean Differences between patients with and without HbA1c value				
	HbA1c present	Missing HbA1c	p	SMD
n	765	1337		
antihypertensive_12mths = 1 (%)	719 (94.0)	1257 (94.0)	1	0.0
Age_Medication (mean (SD))	68.89 (10.8)	68.85 (11.4)	0.9	0.0
hyperglycemia = 1 (%)	364 (47.6)	641 (47.9)	0.9	0.0
dementia = 1 (%)	24 (3.1)	44 (3.3)	0.9	0.01
insulin_4mths = 1 (%)	206 (26.9)	354 (26.5)	0.9	0.01
Female = 1 (%)	425 (55.6)	756 (56.5)	0.7	0.02
pulmonary_hypertension = 1 (%)	4 (0.5)	10 (0.7)	0.7	0.03
alzheimers_disease = 1 (%)	8 (1.0)	18 (1.3)	0.7	0.03
Outcome_MACE (mean (SD))	0.09 (0.3)	0.10 (0.3)	0.5	0.03
hospitalizations_12mths (mean (SD))	0.32 (0.8)	0.30 (0.7)	0.5	0.03
time_to_event_MACE (mean (SD))	276.9 (110.2)	281.7 (109.2)	0.3	0.04
unstable_angina = 1 (%)	1 (0.1)	5 (0.4)	0.6	0.05
obesity_diagnosis = 1 (%)	1 (0.1)	5 (0.4)	0.6	0.05
anticoagulant_12mths = 1 (%)	89 (11.6)	178 (13.3)	0.3	0.05
Faurot_Frailty_Index (mean (SD))	0.06 (0.07)	0.06 (0.07)	0.2	0.05
colonscopy_12mths = 1 (%)	42 (5.5)	58 (4.3)	0.3	0.05
diabetes_circulatory_disorders = 1 (%)	55 (7.2)	116 (8.7)	0.3	0.06
ed_visits_12mths (mean (SD))	0.85 (2.5)	0.99 (2.2)	0.2	0.06
statins_12mths = 1 (%)	612 (80.0)	1036 (77.5)	0.2	0.06
stroke_tia = 1 (%)	44 (5.8)	101 (7.6)	0.1	0.07
acute_kidney_injury = 1 (%)	48 (6.3)	110 (8.2)	0.1	0.08
anemia = 1 (%)	199 (26.0)	393 (29.4)	0.1	0.08
flu_shot_12mths = 1 (%)	36 (4.7)	94 (7.0)	0	0.10
atrial_fib = 1 (%)	88 (11.5)	203 (15.2)	0	0.11
COPD = 1 (%)	76 (9.9)	179 (13.4)	0	0.11
chronic_kidney_disease = 1 (%)	162 (21.2)	226 (16.9)	0	0.11
diabetic_neuropathy = 1 (%)	168 (22.0)	357 (26.7)	0	0.11
endocrinology_visits_12mths (mean (SD))	0.12 (0.56)	0.06 (0.47)	0	0.11
Race (%)			0	0.12
1_White	486 (63.5)	852 (63.7)		
2_Black	229 (29.9)	358 (26.8)		
3_Other	50 (6.5)	127 (9.5)		
depression = 1 (%)	123 (16.1)	156 (11.7)	0	0.13

Table cont: Standardized Mean Differences between patients with and without HbA1c value				
	HbA1c present	Missing HbA1c	p	SMD
Charlson_Index (%)			0.1	0.14
0	32 (4.2)	66 (4.9)		
1	251 (32.8)	359 (26.9)		
2	107 (14.0)	188 (14.1)		
3	116 (15.2)	234 (17.5)		
4	85 (11.1)	160 (12.0)		
5+	174 (22.7)	330 (24.7)		
antiplatelet_12mths = 1 (%)	88 (11.5)	221 (16.5)	0	0.15
cardiomyopathy = 1 (%)	47 (6.1)	139 (10.4)	0	0.16
metformin_4mths = 1 (%)	528 (69.0)	821 (61.4)	0	0.16
MedicarePartD_costshare = 1 (%)	284 (37.1)	607 (45.4)	<0.001	0.17
Exposure_medication = 2_sglt2i (%)	108 (14.1)	279 (20.9)	<0.001	0.18
sulfonylureas_4mths = 1 (%)	373 (48.8)	464 (34.7)	<0.001	0.39
internal_med_12mths (mean (SD))	3.38 (3.21)	2.33 (3.48)	<0.001	0.31

Table: Standardized Mean Differences between patients with and without BMI value				
	BMI Present	Missing BMI	p	SMD
n	1756	346		
diabetes_circulatory_disorders = 1 (%)	143 (8.1)	28 (8.1)	1.00	0.0
Female = 1 (%)	987 (56.2)	194 (56.1)	1.00	0.0
sulfonylureas_4mths = 1 (%)	700 (39.9)	137 (39.6)	0.97	0.01
Outcome_MACE (mean (SD))	0.10 (0.30)	0.10 (0.29)	0.88	0.01
Exposure_medication = 2_sglT2i (%)	325 (18.5)	62 (17.9)	0.86	0.02
time_to_event_MACE (mean (SD))	279.64 (109.4)	281.56 (110.8)	0.77	0.02
flu_shot_12mths = 1 (%)	110 (6.3)	20 (5.8)	0.83	0.02
endocrinology_visits_12mths (mean (SD))	0.08 (0.47)	0.07 (0.66)	0.64	0.02
MedicarePartD_costshare = 1 (%)	748 (42.6)	143 (41.3)	0.71	0.03
antihypertensive_12mths = 1 (%)	1653 (94.1)	323 (93.4)	0.66	0.03
insulin_4mths = 1 (%)	472 (26.9)	88 (25.4)	0.63	0.03
antiplatelet_12mths = 1 (%)	262 (14.9)	47 (13.6)	0.58	0.04
dementia = 1 (%)	59 (3.4)	9 (2.6)	0.57	0.05
metformin_4mths = 1 (%)	1119 (63.7)	230 (66.5)	0.36	0.06
diabetic_neuropathy = 1 (%)	446 (25.4)	79 (22.8)	0.35	0.06
statins_12mths = 1 (%)	1385 (78.9)	263 (76.0)	0.27	0.07
alzheimers_disease = 1 (%)	24 (1.4)	2 (0.6)	0.34	0.08
anemia = 1 (%)	505 (28.8)	87 (25.1)	0.19	0.08
unstable_angina = 1 (%)	6 (0.3)	0 (0.0)	0.59	0.08
obesity_diagnosis = 1 (%)	6 (0.3)	0 (0.0)	0.59	0.08
Age (mean (SD))	68.69 (11.0)	69.75 (12.0)	0.11	0.09
ed_visits_12mths (mean (SD))	0.97 (2.4)	0.77 (1.6)	0.15	0.10
colonoscopy_12mths = 1 (%)	89 (5.1)	11 (3.2)	0.17	0.10
Race (%)			0.22	0.10
1_White	1132 (64.5)	206 (59.5)		
2_Black	479 (27.3)	108 (31.2)		
3_Other	145 (8.3)	32 (9.2)		
stroke_tia = 1 (%)	113 (6.4)	32 (9.2)	0.08	0.11
hyperglycemia = 1 (%)	855 (48.7)	150 (43.4)	0.08	0.11
Faurot_Frailty_Index (mean (SD))	0.06 (0.06)	0.06 (0.08)	0.05	0.11
depression = 1 (%)	244 (13.9)	35 (10.1)	0.07	0.12
pulmonary_hypertension = 1 (%)	14 (0.8)	0 (0.0)	0.19	0.13
acute_kidney_injury = 1 (%)	141 (8.0)	17 (4.9)	0.06	0.13
COPD = 1 (%)	226 (12.9)	29 (8.4)	0.03	0.15
atrial_fib = 1 (%)	258 (14.7)	33 (9.5)	0.01	0.16
anticoagulant_12mths = 1 (%)	238 (13.6)	29 (8.4)	0.01	0.17
cardiomyopathy = 1 (%)	169 (9.6)	17 (4.9)	0.01	0.18
chronic_kidney_disease = 1 (%)	345 (19.6)	43 (12.4)	0.00	0.20

Table con't: Standardized Mean Differences between patients with and without BMI value				
	BMI Present	Missing BMI	p	SMD
internal_med_12mths (mean (SD))	2.83 (3.42)	2.12 (3.33)	<0.001	0.21
hospitalizations_12mths (mean (SD))	0.33 (0.76)	0.19 (0.53)	0.00	0.22
Charlson_Index (%)			0.00	0.24
0.00	77 (4.4)	21 (6.1)		
1.00	483 (27.5)	127 (36.7)		
2.00	250 (14.2)	45 (13.0)		
3.00	294 (16.7)	56 (16.2)		
4.00	212 (12.1)	33 (9.5)		
5+	440 (25.1)	64 (18.5)		

References

1. Jensen, P.N., et al., *A systematic review of validated methods for identifying atrial fibrillation using administrative data*. *Pharmacoepidemiol Drug Saf*, 2012. **21 Suppl 1**(0 1): p. 141-7.
2. Piccini, J.P., et al., *Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007*. *Circ Cardiovasc Qual Outcomes*, 2012. **5**(1): p. 85-93.
3. Shah, R.U., et al., *Impact of Different Electronic Cohort Definitions to Identify Patients With Atrial Fibrillation From the Electronic Medical Record*. *J Am Heart Assoc*, 2020. **9**(5): p. e014527.
4. Lipska, K.J., et al., *National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011*. *JAMA Intern Med*, 2014. **174**(7): p. 1116-24.
5. Birman-Deych, E., et al., *Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors*. *Med Care*, 2005. **43**(5): p. 480-5.
6. Faurot, K.R., et al., *Using claims data to predict dependency in activities of daily living as a proxy for frailty*. *Pharmacoepidemiol Drug Saf*, 2015. **24**(1): p. 59-66.
7. Marcum, Z.A., et al., *Association of New Use of Antihypertensives That Stimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries*. *JAMA Netw Open*, 2023. **6**(1): p. e2249370.